生长抑素、奥美拉唑与凝血酶联合治疗上消化道溃疡性出血的临床观察

摘要/Abstract

摘要： 目的评价生长抑素、奥美拉唑与凝血酶联合治疗上消化道溃疡性出血的临床疗效与安全性,为该方案的临床应用奠定基础。方法选取我院2011年3月~2015年3月收治的100例上消化道溃疡性出血患者,按照随机数字表法分为观察组、对照组,各50例,均给予奥美拉唑治疗,观察组加用生长抑素、凝血酶治疗。比较两组患者治疗情况,血常规、凝血指标及Blatchford评分变化,评价两种治疗方案的临床疗效与安全性。结果观察组止血时间、出血量及住院时间均低于对照组,差异有统计学意义（P<0.05）。两组患者治疗72 h后Hb、RBC、PLT、Hct、FIB均较治疗前升高,WBC、PT、APTT、Blatchford评分均较治疗前降低,观察组Hb、RBC、PLT、Hct及凝血指标、Blatchford评分改善更为明显,差异有统计学意义（P<0.05）。观察组临床总有效率为82.00%,高于对照组的58.00%,差异有统计学意义（P<0.05）;两组患者不良反应发生率均为8.00%,组间比较差异无统计学意义（P>0.05）。结论生长抑素、奥美拉唑与凝血酶联合治疗上消化道溃疡性出血有着确切的临床疗效与良好的安全性,对患者临床症状、凝血功能的早期改善具有积极意义。

关键词: 生长抑素, 奥美拉唑, 凝血酶, 上消化道溃疡性出血, 临床疗效, 安全性

Abstract: Objective To evaluate the clinical efficacy and safety of combined application of somatostatin, omeprazole and thrombin in treatment of upper gastrointestinal ulcer bleeding, and lay a foundation for the application of the treatment.Methods 100 patients with upper gastrointestinal ulcer bleeding from March 2011 to March 2015 in our hospital were selected and divided into the observation group and the control group (50 cases in each group) by the random number table method. All of the patients were treated with omeprazole, while patients in the observation group were treated with the therapy supplementary somatostatin and thrombin. The changes of the hematology test, coagulation indicators and Blatchford scores between the two groups were observed and compared, and the clinical efficacy and safety of the two treatments were evaluated. Results The hemostatic time, hemorrhage volume and hospitalization time in the observation group were lower than those in the control group, the difference was statistically significant (P < 0.05). Compared with the levels before treatment, the Hb, RBC, PLT, Hct, FIB in both of the two groups increased, the WBC, PT, APTT, Blatchford scores decreased after 72 hours treatment, the changes of the observation group were more obvious, the difference was statistically significant (P < 0.05). The clinical total effective rate of the observation group was 82.00%, which was higher than that in the control group of 58.00%, the difference was statistically significant (P < 0.05). The incidence of adverse reactions in both of the two groups was 8.00%, showed no statistical difference (P > 0.05). Conclusion Combined application of somatostatin, omeprazole and thrombin in the treatment of upper gastrointestinal ulcer bleeding has curative effect and good safety, can positively improve the clinical symptoms and blood coagulation function of patients, and it’s worthy of promotion.

Key words: somatostatin, omeprazole, thrombin, upper gastrointestinal ulcer bleeding, clinical efficacy, safety

中图分类号:

R975

芮菊萍. 生长抑素、奥美拉唑与凝血酶联合治疗上消化道溃疡性出血的临床观察[J]. 中国药物警戒, 2016, 13(11): 660-662.

RUI Ju-ping. Clinical Observation of Combined Application of Somatostatin, Omeprazole and Thrombin in Treatment of Upper Gastrointestinal Ulcer Bleeding[J]. Chinese Journal of Pharmacovigilance, 2016, 13(11): 660-662.

参考文献

[1] Major G I. Gastrointestinal bleeding with the new oral anticoagulants-defining the issues and the management strategies[J]. Thrombosis and haemostasis, 2013, 110(2013): 205-212.
[2] 王莉. 消化内科上消化道出血患者42例的临床诊断和治疗[J].转化医学电子杂志, 2015, 2(11): 38.
[3] Fujishiro M, Iguchi M, Kakushima N, et al. Guidelines for endoscopic management of non-variceal upper gastrointestinal bleeding[J].Digestive Endoscopy, 2016, 28(4): 363-378.
[4] Song L M W K, Levy M J. Emerging endoscopic therapies for nonvariceal upper gastrointestinal bleeding[J]. Gastroenterology Clinics of North America, 2014, 43(4): 721-737.
[5] 李晓红. 奥曲肽联合凝血酶治疗肝硬化合并上消化道出血疗效观察[J]. 临床合理用药杂志, 2013, 6(19): 66.
[6] Feinman M, Haut E R. Upper gastrointestinal bleeding[J]. Surgical Clinics of North America, 2014, 94(1): 43-53.
[7] 《中华内科杂志》编委会. 急性非静脉曲张性上消化道出血诊治指南(2009,杭州)[J]. 中华内科杂志, 2009, 48(10): 891-894.
[8] Holster I L, Kuipers E J, Tjwa E. Hemospray in the treatment of upper gastrointestinal hemorrhage in patients on antithrombotic therapy[J]. Endoscopy, 2013, 45(1): 63-66.
[9] 曾德映. 奥曲肽联合凝血酶在肝硬化合并上消化道出血患者中的应用[J]. 中外医疗, 2013, 32(16): 33-34.
[10] 张杏. 凝血酶联合奥美拉唑治疗上消化道出血的疗效分析[J].中国当代医药, 2013, 20(9): 58-59.
[11] Rockey D C. Endoscopy for Gastrointestinal Bleeding in Patients Treated With Direct Oral Anticoagulants[J]. The American Journal of Gastroenterology Supplements, 2016, 3(1): 45-50.
[12] Gralnek I M, Dumonceau J M, Kuipers E J, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage:European Society of Gastrointestinal Endoscopy (ESGE) Guideline[J].Endoscopy, 2015, 47(10): a1-a46.
[13] 宁风. 奥美拉唑联合奥曲肽治疗非静脉曲张性上消化道出血的临床观察[J]. 中国当代医药, 2013, 20(6): 102-103.
[14] Cai Z Y, Yang W, He Y Y, et al. Cefoperazone/Sulbactam-Induced Abdominal Wall Hematoma and Upper Gastrointestinal Bleeding:A Case Report and Review of the Literature[J]. Drug Safety-Case Reports, 2016, 3(1): 1-6.
[15] Desai J C, Chatterjee P, Friedman K, et al. Incidence and Clinical Presentation of Gastrointestinal Bleeding in Atrial Fibrillation Patients Taking Direct Oral Anticoagulants[J]. The American Journal of Gastroenterology Supplements, 2016, 3(1): 13-21.